Tocagen Inc. (TOCA) News
Filter TOCA News Items
TOCA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TOCA News From Around the Web
Below are the latest news stories about Tocagen Inc that investors may wish to consider to help them evaluate TOCA as an investment opportunity.
Tocagen Announces Change to Virtual Format for Special Meeting of StockholdersTocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, it is changing its special meeting of stockholders related to its previously announced proposed merger with Forte Biosciences, Inc. (the "Special Meeting") to a virtual-only format that will be held via live audio webcast. |
Tocagen Reports First Quarter 2020 Financial ResultsSAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a… |
Tocagen Reports Fourth Quarter and Full Year 2019 Financial ResultsSAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of… |
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome StudyHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ... |
Tocagen and Forte Biosciences Announce MergerSAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they… |
Introducing Tocagen (NASDAQ:TOCA), The Stock That Tanked 94%Tocagen Inc. (NASDAQ:TOCA) shareholders should be happy to see the share price up 25% in the last month. But that is... |
Is Tocagen Inc. (TOCA) A Good Stock To Buy?Is Tocagen Inc. (NASDAQ:TOCA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […] |
Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual MeetingTocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) at the Society for Neuro-Oncology (SNO) Annual Meeting. The data were presented on behalf of the Toca 5 clinical investigators by Timothy Cloughesy, M.D., professor of neurology and director of the neuro-oncology program at the University of California, Los Angeles and principal investigator for the Toca 5 trial. |
HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA)Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […] |
Tocagen Reports Third Quarter 2019 Financial Results and Business UpdatesSAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5… |